Presentation | Hubei Gedian Humanwell Pharmaceutical | PDF

CPHI & PMEC China 2024 Ended Successfully

09 Jul 2024

// PRESS RELEASE

Gedian Humanwell successfully passed the EDQM audit

06 Jun 2024

// PRESS RELEASE

2024 CPhI Exhibition Shanghai

22 May 2024

// PRESS RELEASE

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

CPhI Worldwide, Milan

Booth #3G83

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

3 CORPORATE CONTENT #SupplierSpotlight, 3 NEWS #PharmaBuzz

media
3 CORPORATE CONTENT #SupplierSpotlight
3 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

66 All APIs, 17 USDMF, 12 CEP/COS, 1 JDMF, 4 EU WC, 4 KDMF, 23 NDC API, 59 Listed APIs

66 All APIs
17 USDMF
12 CEP/COS
1 JDMF
4 EU WC
4 KDMF
23 NDC API
59 Listed APIs

FINISHED DOSAGE FORMULATIONS

4 FDF Dossiers, 4 FDA Orange Book

4 FDF Dossiers
4 FDA Orange Book

KEY PRODUCTS

Abiraterone Acetate, Abiraterone Decanoate, Drospirenone, Dutasteride, Finasteride, Ganciclovir, Ganciclovir Sodium, Levonorgestrel, Methylprednisolone, Methylprednisolone Aceponate, Methylprednisolone Hemisuccinate, Oxcarbazepine, Progesterone, Testosterone, Testosterone Cypionate, Testosterone Enanthate, Testosterone Propionate, Testosterone Undecanoate

Abiraterone Acetate
Abiraterone Decanoate
Drospirenone
Dutasteride
Finasteride
Ganciclovir
Ganciclovir Sodium
Levonorgestrel
Methylprednisolone
Methylprednisolone Aceponate
Methylprednisolone Hemisuccinate
Oxcarbazepine
Progesterone
Testosterone
Testosterone Cypionate
Testosterone Enanthate
Testosterone Propionate
Testosterone Undecanoate

EXCIPIENTS

21 All Excipients, 21 USDMF

excipientPortfolio
21 All Excipients
21 USDMF

INSPECTIONS & REGISTRATIONS

3 FDA, 1 EDQM, 4 GDUFA

inspections
3 FDA
1 EDQM
4 GDUFA

Hubei Gedian Humanwell focuses on R&D, production, & sales of fertility regulation drugs & steroidal APIs.

About

Hubei Gedian Humanwell Pharmaceutical Co., Ltd. is a modern high-tech pharmaceutical company with a focus on the research and development, production, and sales of fertility regulation drugs and steroidal APIs. It operates as a wholly-owned subsidiary of Humanwell Healthcare Group (Stock Code: 600079), one of the leading pharmaceutical conglomerates in China. The company operates two APIs manufacturing sites, one formulation factory, and one excipients factory, showcasing its commitment to integrating the reproductive health industry chain from raw materials and active pharmaceutical ingredients (APIs) to finished dosage forms.